Journal
ONCOTARGETS AND THERAPY
Volume 12, Issue -, Pages 7329-7336Publisher
DOVE MEDICAL PRESS LTD
DOI: 10.2147/OTT.S218321
Keywords
adjuvant immunotherapies; neoadjuvant immunotherapies; immune checkpoint inhibitor; non-small-cell lung cancer; biomarker; liquid biopsy
Categories
Funding
- National Natural Science Foundation of China [81622001, 91642108, 81802255]
- Shanghai Pujiang Program [17PJD036]
- Shanghai Municipal Commission of Health and Family Planning Program [20174Y0131]
- National Key Research & Development Project [2016YFC0902300]
- Dream Tutor Outstanding Young Talents Program [fkyq1901]
- Shanghai Municipal Health Commission [2017BR026]
- Shanghai Science and Technology Committee [19XD1423200]
- Shanghai Municipal Human Resources and Social Securitiy Bureau [2017114]
- Shanghai Hospital Development Center [SHDC12018122]
- Fundamental Research Funds for the Central Universities [22120180510]
- Shanghai Pulmonary Hospital [fkgg1801, fkcx1904]
- Major Disease Clinical Skills Enhancement Program of three year action plan for promoting clinical skills and clinical innovation in municipal hospitals, Shanghai Shen Kang Hospital Development Center Clinical Research Plan of SHDC [16CR1001A]
Ask authors/readers for more resources
Postoperative patients have risk recurring, even for completed resected early stage non-small-cell lung cancer (NSCLC). To control the recurrence rate, neoadjuvant and adjuvant therapies have been applied widely in clinical practice; however, neoadjuvant and adjuvant immunotherapy clinical trials on NSCLC are still being explored. In this review, we summarized the research progress and outline the issues need to be solved on adjuvant and neoadjuvant immunotherapies in NSCLC.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
